Transforming growth factor-beta 1 delivery from microporous scaffolds decreases inflammation post-implant and enhances function of transplanted islets

Biomaterials

Volumn 80, Issue , 2016, Pages 11-19

  Liu, Jeffrey M H ^a,b   Zhang, Jesse ^c   Zhang, Xiaomin ^d   Hlavaty, Kelan A ^c   Ricci, Christine F ^a   Leonard, Joshua N ^a   Shea, Lonnie D ^b   Gower, R Michael ^e,f  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Northwestern University   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e The Department of Mechanical Engineering   (United States)

^f UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Immunoengineering; Immunomodulation; Leukocyte; Scaffold; Transplant

Indexed keywords

CELLS; CYTOLOGY; SCAFFOLDS; TISSUE; TISSUE REGENERATION; TRANSPLANTS;

BIOMATERIAL IMPLANTATION; BIOMATERIAL SCAFFOLDS; CELL TRANSPLANTATION; IMMUNO MODULATIONS; IMMUNOENGINEERING; INFLAMMATORY RESPONSE; LEUKOCYTE; TRANSFORMING GROWTH FACTOR BETA;

SCAFFOLDS (BIOLOGY);

CD45 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOSE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYGLACTIN; RANTES; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; FLOW CYTOMETRY; GLUCOSE BLOOD LEVEL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; POROSITY; POSTOPERATIVE INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TISSUE REGENERATION; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DIABETES MELLITUS, EXPERIMENTAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; IMMUNOLOGY; IMMUNOMODULATION; PROCEDURES; TISSUE SCAFFOLD;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; CHEMOKINE CCL2; DIABETES MELLITUS, EXPERIMENTAL; DRUG DELIVERY SYSTEMS; IMMUNOMODULATION; INTERLEUKIN-12; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MICE, INBRED C57BL; POROSITY; TISSUE SCAFFOLDS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84951781426     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.11.065     Document Type: Article

References (61)

1. Sanganalmath S.K., Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ. Res. 2013, 113:810-834.
2. Forbes S.J., Gupta S., Dhawan A. Cell therapy for liver disease: From liver transplantation to cell factory. J. Hepatol. 2015, 62:S157-S169.
3. Aboody K., Capela A., Niazi N., Stern J.H., Temple S. Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta stone. Neuron 2011, 70:597-613.
4. Cogger K., Nostro M.C. Recent advances in cell replacement therapies for the treatment of type 1 diabetes. Endocrinology 2015, 156:8-15.
5. Li Y.S., Harn H.J., Hsieh D.K., Wen T.C., Subeq Y.M., Sun L.Y., et al. Cells and materials for liver tissue engineering. Cell Transplant. 2013, 22:685-700.
6. Segers V.F., Lee R.T. Biomaterials to enhance stem cell function in the heart. Circ. Res. 2011, 109:910-922.
7. Orive G., Anitua E., Pedraz J.L., Emerich D.F. Biomaterials for promoting brain protection, repair and regeneration. Nat. Rev. Neurosci. 2009, 10:682-692.
8. Kolaczkowska E., Kubes P. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 2013, 13:159-175.
9. Rocha P.N., Plumb T.J., Crowley S.D., Coffman T.M. Effector mechanisms in transplant rejection. Immunol. Rev. 2003, 196:51-64.
10. Heeger P.S. T-cell allorecognition and transplant rejection: a summary and update. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg. 2003, 3:525-533.
11. Roake J.A., Austyn J.M. The role of dendritic cells and T cell activation in allograft rejection. Exp. Nephrol. 1993, 1:90-101.
12. Clatworthy M.R. B cell responses to allograft-more common than we thought?. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg. 2013, 13:1629-1630.
13. Stolp J., Turka L.A., Wood K.J. B cells with immune-regulating function in transplantation. Nat. Rev. Nephrol. 2014, 10:389-397.
14. Zeng Q., Ng Y.H., Singh T., Jiang K., Sheriff K.A., Ippolito R., et al. B cells mediate chronic allograft rejection independently of antibody production. J. Clin. Investig. 2014, 124:1052-1056.
15. Yang L., Pang Y., Moses H.L. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010, 31:220-227.
16. Kobie J.J., Wu R.S., Kurt R.A., Lou S., Adelman M.K., Whitesell L.J., et al. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res. 2003, 63:1860-1864.
17. Bonham C.A., Lu L., Banas R.A., Fontes P., Rao A.S., Starzl T.E., et al. TGF-beta 1 pretreatment impairs the allostimulatory function of human bone marrow-derived antigen-presenting cells for both naive and primed T cells. Transpl. Immunol. 1996, 4:186-191.
18. Fu S., Zhang N., Yopp A.C., Chen D., Mao M., Chen D., et al. TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25-precursors. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg. 2004, 4:1614-1627.
19. Blomeier H., Zhang X., Rives C., Brissova M., Hughes E., Baker M., et al. Polymer scaffolds as synthetic microenvironments for extrahepatic islet transplantation. Transplantation 2006, 82:452-459.
20. Gibly R.F., Zhang X., Graham M.L., Hering B.J., Kaufman D.B., Lowe W.L., et al. Extrahepatic islet transplantation with microporous polymer scaffolds in syngeneic mouse and allogeneic porcine models. Biomaterials 2011, 32:9677-9684.
21. Chen X., Zhang X., Larson C., Chen F., Kissler H., Kaufman D.B. The epididymal fat pad as a transplant site for minimal islet mass. Transplantation 2007, 84:122-125.
22. Salvay D.M., Rives C.B., Zhang X., Chen F., Kaufman D.B., Lowe W.L., et al. Extracellular matrix protein-coated scaffolds promote the reversal of diabetes after extrahepatic islet transplantation. Transplantation 2008, 85:1456-1464.
23. Hlavaty K.A., Gibly R.F., Zhang X., Rives C.B., Graham J.G., Lowe W.L., et al. Enhancing human islet transplantation by localized release of trophic factors from PLG scaffolds. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg. 2014, 14:1523-1532.
24. Harris L.D., Kim B.S., Mooney D.J. Open pore biodegradable matrices formed with gas foaming. J. Biomed. Mater. Res. 1998, 42:396-402.
25. Gower R.M., Boehler R.M., Azarin S.M., Ricci C.F., Leonard J.N., Shea L.D. Modulation of leukocyte infiltration and phenotype in microporous tissue engineering scaffolds via vector induced IL-10 expression. Biomaterials 2014, 35:2024-2031.
26. Chou C.H., Cheng W.T., Lin C.C., Chang C.H., Tsai C.C., Lin F.H. TGF-beta1 immobilized tri-co-polymer for articular cartilage tissue engineering. J. Biomed. Mater. Res. Part B Appl. Biomater. 2006, 77:338-348.
27. Holland T.A., Tabata Y., Mikos A.G. Dual growth factor delivery from degradable oligo(poly(ethylene glycol) fumarate) hydrogel scaffolds for cartilage tissue engineering. J. Control. Release Off. J. Control. Release Soc. 2005, 101:111-125.
28. Kim S.E., Park J.H., Cho Y.W., Chung H., Jeong S.Y., Lee E.B., et al. Porous chitosan scaffold containing microspheres loaded with transforming growth factor-beta1: implications for cartilage tissue engineering. J. Control. Release Off. J. Control. Release Soc. 2003, 91:365-374.
29. Lee J.E., Kim S.E., Kwon I.C., Ahn H.J., Cho H., Lee S.H., et al. Effects of a chitosan scaffold containing TGF-beta1 encapsulated chitosan microspheres on in vitro chondrocyte culture. Artif. Organs 2004, 28:829-839.
30. Cucchiarini M., Sohier J., Mitosch K., Kaul G., Zurakowski D., Bezemer J., et al. Effect of transforming growth factor-beta 1 (TGF-ß1) released from a scaffold on chondrogenesis in an osteochondral defect model in the rabbit. Centeurjbiol. 2006, 1:43-60.
31. Fan H., Hu Y., Qin L., Li X., Wu H., Lv R. Porous gelatin-chondroitin-hyaluronate tri-copolymer scaffold containing microspheres loaded with TGF-beta1 induces differentiation of mesenchymal stem cells in vivo for enhancing cartilage repair. J. Biomed. Mater. Res. Part A 2006, 77:785-794.
32. Holland T.A., Bodde E.W., Cuijpers V.M., Baggett L.S., Tabata Y., Mikos A.G., et al. Degradable hydrogel scaffolds for in vivo delivery of single and dual growth factors in cartilage repair. Osteoarthr. Cartil. OARS Osteoarthr. Res. Soc. 2007, 15:187-197.
33. Kubiczkova L., Sedlarikova L., Hajek R., Sevcikova S. TGF-beta - an excellent servant but a bad master. J. Transl. Med. 2012, 10:183.
34. Wahl S.M., Hunt D.A., Wakefield L.M., McCartney-Francis N., Wahl L.M., Roberts A.B., et al. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:5788-5792.
35. Olieslagers S., Pardali E., Tchaikovski V., ten Dijke P., Waltenberger J. TGF-beta1/ALK5-induced monocyte migration involves PI3K and p38 pathways and is not negatively affected by diabetes mellitus. Cardiovasc. Res. 2011, 91:510-518.
36. Geissmann F., Revy P., Regnault A., Lepelletier Y., Dy M., Brousse N., et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol. 1999, 162:4567-4575.
37. Gong D., Shi W., Yi S.J., Chen H., Groffen J., Heisterkamp N. TGFbeta signaling plays a critical role in promoting alternative macrophage activation. BMC Immunol. 2012, 13:31.
38. Leshansky L., Aberdam D., Itskovitz-Eldor J., Berrih-Aknin S. Human embryonic stem cells prevent T-cell activation by suppressing dendritic cells function via TGF-beta signaling pathway. Stem Cells 2014, 32:3137-3149.
39. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Investig. 2003, 112:1796-1808.
40. Jenney C.R., Anderson J.M. Adsorbed serum proteins responsible for surface dependent human macrophage behavior. J. Biomed. Mater. Res. 2000, 49:435-447.
41. McNally A.K., Jones J.A., Macewan S.R., Colton E., Anderson J.M. Vitronectin is a critical protein adhesion substrate for IL-4-induced foreign body giant cell formation. J. Biomed. Mater. Res. Part A 2008, 86:535-543.
42. Geissmann F., Jung S., Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82.
43. Romagnani P., Crescioli C. CXCL10: a candidate biomarker in transplantation. Clinica Chimica Acta Int. J. Clin. Chem. 2012, 413:1364-1373.
44. Agostini C., Calabrese F., Rea F., Facco M., Tosoni A., Loy M., et al. Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am. J. Pathol. 2001, 158:1703-1711.
45. Piccotti J.R., Li K., Chan S.Y., Eichwald E.J., Bishop D.K. Interleukin-12 (IL-12)-driven alloimmune responses in vitro and in vivo: requirement for beta1 subunit of the IL-12 receptor. Transplantation 1999, 67:1453-1460.
46. Shen H., Goldstein D.R. IL-6 and TNF-alpha synergistically inhibit allograft acceptance. J. Am. Soc. Nephrol. JASN 2009, 20:1032-1040.
47. Saraiva M., O'Garra A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 2010, 10:170-181.
48. Lin H.M., Lee J.H., Yadav H., Kamaraju A.K., Liu E., Zhigang D., et al. Transforming growth factor-beta/Smad3 signaling regulates insulin gene transcription and pancreatic islet beta-cell function. J. Biol. Chem. 2009, 284:12246-12257.
49. Ferrari G., Cook B.D., Terushkin V., Pintucci G., Mignatti P. Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J. Cell. Physiol. 2009, 219:449-458.
50. Arita S., Une S., Ohtsuka S., Atiya A., Kasraie A., Shevlin L., et al. Prevention of primary islet isograft nonfunction in mice with pravastatin. Transplantation 1998, 65:1429-1433.
51. Wood K.J., Goto R. Mechanisms of rejection: current perspectives. Transplantation 2012, 93:1-10.
52. Morais J.M., Papadimitrakopoulos F., Burgess D.J. Biomaterials/tissue interactions: possible solutions to overcome foreign body response. AAPS J. 2010, 12:188-196.
53. Wyburn K.R., Jose M.D., Wu H., Atkins R.C., Chadban S.J. The role of macrophages in allograft rejection. Transplantation 2005, 80:1641-1647.
54. Zecher D., van Rooijen N., Rothstein D.M., Shlomchik W.D., Lakkis F.G. An innate response to allogeneic nonself mediated by monocytes. J. Immunol. 2009, 183:7810-7816.
55. Vassalli G. Dendritic cell-based approaches for therapeutic immune regulation in solid-organ transplantation. J. Transplant. 2013, 2013:761429.
56. Oberbarnscheidt M.H., Zeng Q., Li Q., Dai H., Williams A.L., Shlomchik W.D., et al. Non-self recognition by monocytes initiates allograft rejection. J. Clin. Investig. 2014, 124:3579-3589.
57. Beilke J.N., Kuhl N.R., Van Kaer L., Gill R.G. NK cells promote islet allograft tolerance via a perforin-dependent mechanism. Nat. Med. 2005, 11:1059-1065.
58. Liu W., Xiao X., Demirci G., Madsen J., Li X.C. Innate NK cells and macrophages recognize and reject allogeneic nonself in vivo via different mechanisms. J. Immunol. 2012, 188:2703-2711.
59. Makhlouf L., Yamada A., Ito T., Abdi R., Ansari M.J., Khuong C.Q., et al. Allorecognition and effector pathways of islet allograft rejection in normal versus nonobese diabetic mice. J. Am. Soc. Nephrol. JASN 2003, 14:2168-2175.
60. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11:723-737.
61. Bryant J., Hlavaty K.A., Zhang X., Yap W.T., Zhang L., Shea L.D., et al. Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantation. Biomaterials 2014, 35:8887-8894.